title: The Role of Different Supplements in Expression Level of Monoclonal Antibody against Human CD20.
abstract: BACKGROUND
  Recombinant monoclonal antibodies have been marketed in last three decades as the major therapeutic proteins against different cancers. However choosing a proper medium and supplements to reach the high expression is a challenging step. Despite of commercial serum free and chemically defined media, there are still numerous researches seeking the optimum media to gain higher expression titer. Selecting the best basal media followed by proper supplementation to increase the cell density and expression titer needs proper and accurate investigation.
  
  
  METHODS
  In this study, we have determined the expression titer of monoclonal antibody against human CD20 using soy extract, Essential Amino Acid, Non-Essential Amino Acid, Panexin NTS, Peptone, Yeast extract, Insulin-transferrin selenite, Human Serum Albumin, Bovine Serum Albumin, Lipid, and two commercially available supplements, Power and Xtreme feed. In each experiment, the expression level was compared with a well defined media, ProCHO5, RPMI 1640 and DMEM-F12.
  
  
  RESULTS
  It has been shown that supplementing the ProCHO5 basal medium with 10% power feed or combination of 5% PanexinNTS,1.5 g/L yeast and 1.5g/L peptone results in the best production levels with 450 and 425 mg/L of anti CD20 mAb expression level, respectively.
  
  
  CONCLUSIONS
  Panexin NTS, yeast and peptone cane be proper supplement for fed-batch cell culture instead of commercial Power feed supplement which is a cost effective way to increase expression level. And thereby ProCHO5 may be replaced with common media such as RPMI 1640 and DMEM-F12.
authors.affiliation: Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Fereidoun
authors.initials: F
authors.lastname: Mahboudi
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Abolhassan
authors.forename: Armita
authors.initials: A
authors.lastname: Azarpanah
authors.forename: Hamideh
authors.initials: H
authors.lastname: Aghajani-Lazarjani
authors.forename: Mohammad Amin
authors.initials: MA
authors.lastname: Sadeghi-Haskoo
authors.forename: Shaian
authors.initials: S
authors.lastname: Maleknia
authors.forename: Behrouz
authors.initials: B
authors.lastname: Vaziri
keywords: CHO cells; Gene expression; Monoclonal antibody
references.citation: Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):671-85
references.pmid: 16822577
references.citation: Biotechnol Bioeng. 2005 Jan 20;89(2):164-77
references.pmid: 15593097
references.citation: Cytotechnology. 2008 Jun;57(2):187-97
references.pmid: 19003165
references.citation: J Biosci Bioeng. 2012 Sep;114(3):347-52
references.pmid: 22652083
references.citation: J Immunol Methods. 1980;39(4):369-75
references.pmid: 7007516
references.citation: Biotechnol Bioeng. 2011 Dec;108(12):3025-31
references.pmid: 21769861
references.citation: Cytotechnology. 2000 Feb;32(2):157-67
references.pmid: 19002977
references.citation: Cytotechnology. 2004 Mar;44(3):103-14
references.pmid: 19003233
references.citation: BMC Proc. 2011 Nov 22;5 Suppl 8:P75
references.pmid: 22373129
references.citation: Eur J Pharm Biopharm. 2011 Jun;78(2):184-8
references.pmid: 21256214
references.citation: Biotechnol Prog. 1995 Jan-Feb;11(1):1-13
references.pmid: 7765983
references.citation: Biotechnol Bioeng. 1994 May;43(11):1175-89
references.pmid: 18615531
references.citation: Appl Microbiol Biotechnol. 2012 Feb;93(3):917-30
references.pmid: 22159888
references.citation: Biotechnol Prog. 2011 May-Jun;27(3):796-802
references.pmid: 21509955
references.citation: J Biotechnol. 1996 Jul 18;48(1-2):161-73
references.pmid: 8818281
references.citation: MAbs. 2010 Sep-Oct;2(5):466-79
references.pmid: 20622510
references.citation: Appl Microbiol Biotechnol. 2005 Aug;68(3):283-91
references.pmid: 15834715
references.citation: MAbs. 2009 Sep-Oct;1(5):443-52
references.pmid: 20065641